What is DNTH's P/E ratio?

Dianthus Therapeutics Inc. (DNTH) currently trades at a P/E ratio of 59.70.

Dianthus Therapeutics Inc. reports a Return on Equity (ROE) of -0.94%.

What is DNTH's dividend yield?

Dianthus Therapeutics Inc. offers a dividend yield of 0.00%.

What is DNTH's Quality Score?

Our AI rates DNTH's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy DNTH?

Our AI Timing Score for DNTH is 91 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does DNTH belong to?

Dianthus Therapeutics Inc. is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

Dianthus Therapeutics Inc. (DNTH) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-03 | FS: 2026-03-31)

DNTH AI Analysis Summary

Our AI summary for DNTH: Dianthus Therapeutics Inc. (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 59.70, ROE of -0.94%, a dividend yield of 0.00%. Its financial Quality Score stands at 23/100 — fundamentals below the market average. The AI Timing Score is 91/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

DNTH

Dianthus Therapeutics Inc.

US:NASDAQ STOCK Healthcare >> Biotechnology News 75

USD 106.02

-0.90 (-0.84%) Day Change

Watchlist Portfolio Compare Chart

59.70

P/E

0.00

D/E

-0.9%

ROE

-0.9%

ROA

0.00%

Div Yield

18.26

PEG

DIANTHUS THERAPEUTICS INC.
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 106.02 Price -0.90 (-0.84%) Day Change	NEWS SCORE: 75

DNTH, the overall quality is not good ( Quality = 23) but the timing to buy is ...(Sign In to See)...

Loading chart...

23 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: P/E ratio is relatively high
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is ok , ...

Quality Factors

39%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	75
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	106.02
PBV / Sector	4.87 / 44,219.29
Earning Per Share	-0.21

PE / Sector	59.70 / 19.28
PEG or PE/Growth / Sector	18.26 / 1.23
Average 1M Daily Value	88.51 M
Average 1W Daily Value	86.81 M

Timing Factors

71%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

37%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

60%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-847.53 / 98.22
NPM Average (%) / Sector	-2,433.72 / -1,697.63
NPM Change Average (%) / Sector	157.86 / 5,097.97 GREAT
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-0.91 / 185,260.96
ROA Average (%) / Sector	-22.55 / 36,684.70
ROA Change Average (%) / Sector	-24.50 / 422,221.66
ROE (%) / Sector	-0.94 / 243,762.23
ROE Average (%) / Sector	-24.48 / 48,758.47
ROE Change Average (%) / Sector	-25.12 / 424,968.10
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -0.19

Registration Details

Analyze Date	2026-08-04 08:01:24
Symbol	DNTH
Name	DIANTHUS THERAPEUTICS INC.
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	54.67 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	5,844.91 / 9,645.64

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 7 Times Square, New York, NY, United States, 10036

Phone: 929 999 4055

Website: https://dianthustx.com

Employees: 92

Sector: Healthcare >> Biotechnology

Description: Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.